XT
AVTX icon

XTX Topco’s Avalo Therapeutics AVTX Stock Holding History

XTX Topco’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$972K Sell
52,583
-74,149
-59% -$1.17M 0.01% 1816
2026
Q1 		$1.89M Buy
126,732
+86,274
+213% +$1.35M 0.03% 876
2025
Q4 		$735K Buy
40,458
+26,508
+190% +$447K 0.02% 1273
2025
Q3 		$177K Buy
+13,950
New +$120K 0.01% 1888
2023
Q4 		– Sell
-77
Closed -$2.23K – 1585
2023
Q3 		$2.23K Buy
+77
New +$3.44K ﹤0.01% 1493
2022
Q1 		– Sell
-4
Closed -$20K – 673
2021
Q4 		$20K Buy
+4
New +$24K 0.01% 627

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

XTX Topco's AVTX Position: Q2 2026 in Review

XTX Topco reduced its Avalo Therapeutics (AVTX) stake by 59% in Q2 2026, selling an estimated $1.17M and leaving 52,583 shares worth $972K. The position accounts for 0.01% of the portfolio, ranked #1816.

XTX Topco first reported a position in AVTX in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.89M in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • XTX Topco held 52,583 shares of Avalo Therapeutics worth $972K as of Q2 2026.
  • XTX Topco sold 74,149 Avalo Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Avalo Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1816 holding.
  • XTX Topco first reported a position in Avalo Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • XTX Topco's Avalo Therapeutics position peaked at $1.89M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.